Bind appoints CEO
This article was originally published in Scrip
Bind Therapeutics, a clinical-stage nanomedicine platform company developing targeted therapeutics called Accurins, has named Andrew Hirsch acting president and CEO. Mr Hirsch was formerly Bind's chief operating officer and chief financial officer. He replaces Scott Minick, who will remain a member of the company's board of directors. Bind intends to announce a permanent CEO following an "expeditious evaluation of internal and external candidates."
You may also be interested in...
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.